Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00040755 · ClinicalTrials.gov registry record · Phase 2
BMS-275291 in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy
A Phase 2 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
- 68
- Enrollment target
NCT00040755: Completed Phase 2 study, sponsored by National Cancer Institute (NCI).
NCT00040755 is a Phase 2 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 68 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00040755, a Phase 2 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 68 participants
- Enrollment target
Study Summary
BMS-275291 may stop the growth of prostate cancer by stopping blood flow to the tumor and by blocking the enzymes necessary for tumor cell growth. Randomized phase II trial to study the effectiveness of BMS-275291 in treating patients who have prostate cancer that has not responded to hormone therapy
Interventions
- OTHER laboratory biomarker analysis
- DRUG rebimastat
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 68 participants |
| Start Date | 2002-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00040755
The ClinicalTrials.gov registry entry for NCT00040755 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 68 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which laboratory biomarker analysis is the first listed.
NCT00040755 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00040755 about?
NCT00040755 is a clinical study titled "BMS-275291 in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy". BMS-275291 may stop the growth of prostate cancer by stopping blood flow to the tumor and by blocking the enzymes necessary for tumor cell growth. Randomized phase II trial to study the effectiveness of BMS-275291 in treating patients who have prostate cancer that has not responded to hormone therap...
What is the current status of trial NCT00040755?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 68 participants. The study started on 2002-05.
What interventions are being tested in trial NCT00040755?
The interventions under investigation include: laboratory biomarker analysis (OTHER), rebimastat (DRUG).
Who is sponsoring clinical trial NCT00040755?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.